MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a
BALTIMORE, Nov. 21, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company, today revealed groundbreaking insights into the cognitively enhancing effects of MIRA1a in normal mice during a presentation at the University of Louisville's Christine Lee Brown Envirome Institute's Grand Rounds from Dr. Adam Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA Pharmaceuticals and Adjunct Faculty member at the Johns Hopkins School of Medicine.
- Unprecedented Cognitive Boost: MIRA1a demonstrated a doubling of the performance of normal adult mice in learning and memory tests, showcasing MIRA1a's potential to elevate cognitive abilities beyond normal thresholds.
- "The revelation of MIRA1a's dramatic cognitive enhancement potential acutely after even a single dose marks a seismic shift in neuropsychiatric research," said Dr. Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA.
- "This discovery positions MIRA Pharmaceuticals at the forefront of transformative developments in psychotropic drug innovation."
- Erez Aminov, Chief Executive Officer of MIRA, added: "At MIRA Pharmaceuticals, we are committed to seizing industry-defining opportunities.